| Old Articles: <Older 3521-3530 Newer> |
 |
The Motley Fool September 13, 2004 Rich Smith |
Russian Bear Gains Weight Despite a spate of bad news, Russia's economy continues to grow. By buying into some gold-standard U.S. companies, an investor can partake of Russia's growth while considerably limiting the risk of suffering a "YUKOS."  |
The Motley Fool September 13, 2004 Rich Duprey |
A Bird's-Eye Test for Profits Comparing operating cash flows with net income lets investors weed out disasters early. Take a look at Best Buy and Circuit City.  |
The Motley Fool September 13, 2004 Dave Marino-Nachison |
Brillian Blows It Component problems meant the company's new big screens missed the NFL's kickoff party. Revenue guidance for the quarter was dropped to $800,000 at the most, down from initial estimates of between $2.8 million and $3.2 million.  |
The Motley Fool September 13, 2004 David Meier |
Turned Off by Visteon The company's outlook is dark as the automotive supplier loses a substantial amount of business from its number one customer -- Ford.  |
The Motley Fool September 13, 2004 Steven Mallas |
The Force Is With Fox The Star Wars trilogy will be out on DVD soon. How will Fox fare? Iinvestors -- particularly new ones -- should be wary of picking up shares in the company based on the DVD.  |
The Motley Fool September 13, 2004 Tim Beyers |
Is US Airways Grounded? A second bankruptcy filing comes after a month of warnings and a failure to secure labor concessions.  |
The Motley Fool September 13, 2004 Rick Aristotle Munarriz |
Eyes on Eisner Folks who bought into the company five years ago are sporting a loss on paper. Disney's CEO gets ready to move on.  |
The Motley Fool September 13, 2004 Mathew Emmert |
Extra Dividends, Extra Growth A dividend strategy is eminently more rewarding than you think.  |
The Motley Fool September 13, 2004 Selena Maranjian |
Home Depot, Urban-Style Big profits are lurking in big cities for companies willing to change a bit.  |
BusinessWeek September 20, 2004 Amy Barrett |
Merck: Who Will Revive The Giant? Earnings and new-drug disappointments have investors worried about succession.  |
| <Older 3521-3530 Newer> Return to current articles. |